Clinical trials: Gastrointestinal Cancer
Colorectal Cancer, Anastomosis
Safe Anastomosis Feasibility Study
A clinical trial to assess the efficacy, mechanism of action and safety of the Colovac+ Colorectal Anastomosis Protection Device in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection…
- Trial name
- SAFE2019 (NCT05180565)
- Testing
- Colovac
- Where
- 7 sites in Belgium, France
- Volunteers
- 27 people
- Sponsor
- SafeHeal Inc
Hepatocellular Carcinoma
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy.
- Trial name
- METIV-HCC (NCT01755767)
- Testing
- Tivantinib
- Where
- 112 sites in United States, Argentina and 14 more
- Volunteers
- 383 people
- Sponsor
- Daiichi Sankyo
Colorectal Cancer, Colorectal Polyp
Feasibility and Safety of MiWEndo-assisted Colonoscopy
The study involves the planned use of a new microwave-based device during colonoscopy procedures in a small group of patients to assess the preliminary safety of its use and lack of normal clinical practice modification.
- Conditions
- Colorectal Cancer, Colorectal Polyp, Colorectal Adenoma, Colorectal Neoplasms
- Trial name
- MiWEndo1 (NCT05477836)
- Testing
- MiWEndo-assisted colonoscopy
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- MiWEndo Solutions S.L.
Adenocarcinoma of the Pancreas, Pancreatic Cancer
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
The investigators hypothesized that with the administration of the nutritional supplement Ocoxin-Viusid® is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients diagnosed with…
- Conditions
- Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms
- Trial name
- NCT03717298
- Testing
- Ocoxin-Viusid®
- Where
- Cuba
- Volunteers
- 30 people
- Sponsor
- Catalysis SL
Head and Neck Cancer, Lung Cancer
Clinical Evaluation of the New Hypoxia Imaging Agent HX4
Positron Emission Tomography (PET) with fluorine-18 fluoromisonidazole (FMISO) has been used for several years as a non invasive imaging technique to study tumor hypoxia.
- Conditions
- Head and Neck Cancer, Lung Cancer, Liver Cancer
- Trial name
- NCT01213030
- Testing
- [F-18] FMISO, [F-18] HX4
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Siemens Molecular Imaging
Colorectal Cancer
An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin
The overall purpose of this study is to determine the efficacy, safety and tolerability of indisulam in combination with irinotecan as a treatment for patients with metastatic colorectalcancer previously treated with…
- Trial name
- NCT00165867
- Testing
- E7070
- Where
- 7 sites in France, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Eisai Limited
Colorectal Cancer
Evaluation of CG-100 Intraluminal Bypass Device
Evaluation of CG-100 Intraluminal Bypass device
- Trial name
- NCT05632744
- Testing
- CG-100 Intraluminal Bypass Device
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Colospan Ltd.
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- innovaTV 207 (NCT03485209)
- Testing
- tisotumab vedotin, pembrolizumab, carboplatin
- Where
- 175 sites in United States, Canada and 5 more
- Volunteers
- 350 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Advanced Gastric Cancer
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
This study will assess the safety and efficacy of AUY922, when administered, in combination with trastuzumab in adult patients with HER2+ advanced gastric cancer, who have received trastuzumab plus chemotherapy in the first line.
- Trial name
- NCT01402401
- Testing
- AUY922, Trastuzumab
- Where
- 15 sites in United States, Belgium and 6 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Evaluate efficacy and safety of ADI-PEG 20 in patients with high-argininephenotypic and HCC
- Trial name
- NCT05317819
- Testing
- ADI-PEG20
- Where
- 11 sites in Taiwan, Vietnam
- Volunteers
- 300 people
- Sponsor
- Polaris Group
Pancreatic Adenocarcinoma
Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)
The study is a prospective, double arm, non-randomized, open label pilot trial, designed to study the safety, feasibility and preliminary efficacy of a medical device, the NovoTTF-100L concomitant with gemcitabine or concomitant…
- Trial name
- NCT01971281
- Testing
- NovoTTF-100L, Gemcitabine, nab-Paclitaxel
- Where
- 6 sites in Spain, Switzerland
- Volunteers
- 40 people
- Sponsor
- NovoCure Ltd.
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Advanced Solid Tumor, Non-Small Cell Lung Cancer
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases.
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT05757492
- Testing
- CHS-006 (anti-TIGIT), toripalimab (anti-PD-1)
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Coherus Oncology, Inc.
Metastatic Colorectal Cancer
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant…
- Trial name
- NCT05743036
- Testing
- ZN-c3, Encorafenib, Cetuximab
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 44 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550)
Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment
This is a Phase I, single-center, open-label, parallel-group study. A single oral dose of MDR-001, a GLP-1 receptor agonist, will be administered to participants with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic…
- Trial name
- NCT07550634
- Testing
- MDR-001
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MindRank AI Ltd
Advanced Solid Malignancies
A Study of MEDI-575 in Patients With Advanced Solid Malignancies
The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).
- Trial name
- NCT01102400
- Testing
- MEDI-575
- Where
- 5 sites in Japan
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU.
- Trial name
- NCT02307812
- Testing
- Ramucirumab, Paclitaxel
- Sponsor
- Eli Lilly and Company
Gastrointestinal Stromal Tumor
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
The purpose of this study is to determine if STA-9090 is effective in the treatment of patients with metastatic and/or unresectable GIST.
- Trial name
- NCT01039519
- Testing
- Ganetespib
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Synta Pharmaceuticals Corp.
Colorectal Cancer, Neoplasms
Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
The purpose of this study is to evaluate the efficacy of autologous tumor lysate-pulsed dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).
- Conditions
- Colorectal Cancer, Neoplasms, Intestinal Neoplasms, Digestive System Neoplasms
- Trial name
- NCT02202928
- Testing
- DC-CIK, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Hornetcorn Bio-technology Company, LTD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.